Howard M Sandler - JoVE Visualize

Showing results (171-180 of 234) with videos related to

Pageof 24

Sort By:

The Prostate|July 21, 2025

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following ProstatectomyEmily Chan, Stephanie L Pugh, Jeffry P Simko, et al.

European Urology|June 19, 2024

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601William C Jackson, Ming Tang, Matthew J Schipper, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate CancerW Robert Lee, James J Dignam, Mahul B Amin, et al.

International Journal of Radiation Oncology, Biology, Physics|January 2, 2023

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.

JAMA Oncology|March 14, 2024

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 16, 2015

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapyJoseph R Evans, Shuang Zhao, Stephanie Daignault, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.

International Journal of Radiation Oncology, Biology, Physics|August 2, 2025

Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomyHimanshu R Lukka, Stephanie L Pugh, William U Shipley, et al.

International Journal of Radiation Oncology, Biology, Physics|February 3, 2023

Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.

Pageof 24

Showing results (171-180 of 234) with videos related to

Sort By:

Pageof 24

The Prostate|July 21, 2025

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following ProstatectomyEmily Chan, Stephanie L Pugh, Jeffry P Simko, et al.

European Urology|June 19, 2024

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601William C Jackson, Ming Tang, Matthew J Schipper, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate CancerW Robert Lee, James J Dignam, Mahul B Amin, et al.

International Journal of Radiation Oncology, Biology, Physics|January 2, 2023

Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.

JAMA Oncology|March 14, 2024

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 16, 2015

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapyJoseph R Evans, Shuang Zhao, Stephanie Daignault, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson, Peter T Scardino, Michael W Kattan, et al.

International Journal of Radiation Oncology, Biology, Physics|August 2, 2025

Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomyHimanshu R Lukka, Stephanie L Pugh, William U Shipley, et al.

International Journal of Radiation Oncology, Biology, Physics|February 3, 2023

Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415Jinbing Bai, Stephanie L Pugh, Ronald Eldridge, et al.

Pageof 24